Daniel Wolf Appointed Chief Financial Officer at Theradaptive

Theradaptive has welcomed Daniel Wolf as chief financial officer (CFO). He has more than two decades of leadership experience in the medical device and healthcare sectors, including senior roles at Medtronic and Baxter International.

“We are delighted to welcome Dan to the Theradaptive team,” Theradaptive Founder/CEO Dr. Luis M. Alvarez said. “Dan’s proven track record in financial leadership, strategic growth, and M&A in our specific field of interest will be instrumental as we accelerate towards commercialization of our targeted therapeutic delivery platform. Dan is prepared to manage the rapidly growing interest among strategics and large investors heading into our Series B this summer.”

Wolf most recently served as senior vice president, Chief Strategy and M&A Officer at Baxter International. Before Baxter, he spent more than 12 years at Medtronic, where he held various leadership positions predominantly in the Spine and Biologics division, including president of Medicrea and vice president and general manager of Intelligent Data Solutions. During his tenure at Medtronic, Wolf led major strategic transactions and played a key role in business development, corporate strategy, and healthcare economics.

Wolf earned a bachelor of arts degree in economics from Bowdoin College, an MBA from Harvard Business School, and a master of science degree in health sciences and technology from the Massachusetts Institute of Technology. He currently serves as a board director for SI-Bone.

“Dan is a world-class leader with deep experience across strategy, finance, and M&A in the musculoskeletal space,” Theradaptive board member Jeffrey Dunn commented. “His leadership will be critical as the company continues to grow and engage with key stakeholders across the industry.”

Wolf’s appointment as CFO is part of a broader executive transformation that started with the appointment of Dr. Frank Vizesi as CSO, and continued with the addition of Dunn to the board. All three are seasoned medical device executives that bring a wealth of experience in spine and musculoskeletal in preparation for the highest value creation period in the company’s history.

“Theradaptive’s approach to targeted therapeutic delivery is a game-changer and its commitment to transforming patient care is truly inspiring. I look forward to working with the team to drive the company’s next phase of growth and deliver value to patients, partners, and investors,” Wolf stated.

Theradaptive is a privately held, clinical-stage biologics company developing protein therapeutics for spine, orthopedics, dental, and soft tissue repair and targeted therapeutics in diverse areas such as immuno-oncology. The company leverages its therapeutic delivery platform to deliver recombinant biologics to targeted areas in the body with high precision and persistence to address unmet medical needs.